CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Protein SYS6090 for Liver Cancer in China

Bulletin Express

Aug 19

The Board of CSPC Pharmaceutical Group Limited (CSPC) has announced the formal initiation of a Phase Ib/II clinical trial (Protocol SYS6090-007) evaluating SYS6090 Injection in hepatocellular carcinoma at the first study centre in China.

SYS6090 is classified as a Class 1 therapeutic biological product. The recombinant, fully human fusion protein combines an anti-programmed cell death receptor-1 (PD-1) antibody with interleukin-15 (IL-15). The left arm blocks the PD-1/PD-L1 pathway, while the right arm engages IL-15 receptors, stimulating downstream signalling to activate and expand immune cells. Pre-clinical studies showed significant tumour-growth inhibition, favourable safety and tolerability, and stronger pharmacodynamic activity versus existing PD-1 monoclonal antibodies and IL-15 agents.

Regulatory approval to begin clinical studies was granted by China’s National Medical Products Administration in July 2026. The open-label, multi-centre Phase Ib/II trial will assess safety, tolerability and preliminary efficacy of SYS6090 combination therapy in patients with hepatocellular carcinoma. Subject recruitment and screening are underway.

Based on outcomes from this study, CSPC plans to advance SYS6090 into a Phase III trial to further confirm efficacy and safety in the same indication. The company is currently coordinating additional centres to expand patient enrolment across China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1117085773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117085773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117085773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117085773","market":"hk","top_or_hot":-1,"title":"CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Protein SYS6090 for Liver Cancer in China","media":"Bulletin Express","content":"<p>The Board of CSPC Pharmaceutical Group Limited (CSPC) has announced the formal initiation of a Phase Ib/II clinical trial (Protocol SYS6090-007) evaluating SYS6090 Injection in hepatocellular carcinoma at the first study centre in China.</p>\n<p>SYS6090 is classified as a Class 1 therapeutic biological product. The recombinant, fully human fusion protein combines an anti-programmed cell death receptor-1 (PD-1) antibody with interleukin-15 (IL-15). The left arm blocks the PD-1/PD-L1 pathway, while the right arm engages IL-15 receptors, stimulating downstream signalling to activate and expand immune cells. Pre-clinical studies showed significant tumour-growth inhibition, favourable safety and tolerability, and stronger pharmacodynamic activity versus existing PD-1 monoclonal antibodies and IL-15 agents.</p>\n<p>Regulatory approval to begin clinical studies was granted by China’s National Medical Products Administration in July 2026. The open-label, multi-centre Phase Ib/II trial will assess safety, tolerability and preliminary efficacy of SYS6090 combination therapy in patients with hepatocellular carcinoma. Subject recruitment and screening are underway.</p>\n<p>Based on outcomes from this study, CSPC plans to advance SYS6090 into a Phase III trial to further confirm efficacy and safety in the same indication. The company is currently coordinating additional centres to expand patient enrolment across China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Protein SYS6090 for Liver Cancer in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Protein SYS6090 for Liver Cancer in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-19 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Board of CSPC Pharmaceutical Group Limited (CSPC) has announced the formal initiation of a Phase Ib/II clinical trial (Protocol SYS6090-007) evaluating SYS6090 Injection in hepatocellular carcinoma at the first study centre in China.</p>\n<p>SYS6090 is classified as a Class 1 therapeutic biological product. The recombinant, fully human fusion protein combines an anti-programmed cell death receptor-1 (PD-1) antibody with interleukin-15 (IL-15). The left arm blocks the PD-1/PD-L1 pathway, while the right arm engages IL-15 receptors, stimulating downstream signalling to activate and expand immune cells. Pre-clinical studies showed significant tumour-growth inhibition, favourable safety and tolerability, and stronger pharmacodynamic activity versus existing PD-1 monoclonal antibodies and IL-15 agents.</p>\n<p>Regulatory approval to begin clinical studies was granted by China’s National Medical Products Administration in July 2026. The open-label, multi-centre Phase Ib/II trial will assess safety, tolerability and preliminary efficacy of SYS6090 combination therapy in patients with hepatocellular carcinoma. Subject recruitment and screening are underway.</p>\n<p>Based on outcomes from this study, CSPC plans to advance SYS6090 into a Phase III trial to further confirm efficacy and safety in the same indication. The company is currently coordinating additional centres to expand patient enrolment across China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1117085773","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117085773","pubTimestamp":1787140006,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The Board of CSPC Pharmaceutical Group Limited (CSPC) has announced the formal initiation of a Phase Ib/II clinical trial (Protocol SYS6090-007) evaluating SYS6090 Injection in hepatocellular...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团在中国启动新型PD-1/IL-15融合蛋白SYS6090治疗肝癌的Ib/II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"The Board of CSPC Pharmaceutical Group Limited (CSPC) has announced the formal initiation of a Phase Ib/II clinical trial (Protocol SYS6090-007) evaluating SYS6090 Injection in hepatocellular carcinoma at the first study centre in China.\nSYS6090 is classified as a Class 1 therapeutic biological product. The recombinant, fully human fusion protein combines an anti-programmed cell death receptor-1 (PD-1) antibody with interleukin-15 (IL-15). The left arm blocks the PD-1/PD-L1 pathway, while the right arm engages IL-15 receptors, stimulating downstream signalling to activate and expand immune cells. Pre-clinical studies showed significant tumour-growth inhibition, favourable safety and tolerability, and stronger pharmacodynamic activity versus existing PD-1 monoclonal antibodies and IL-15 agents.\nRegulatory approval to begin clinical studies was granted by China’s National Medical Products Administration in July 2026. The open-label, multi-centre Phase Ib/II trial will assess safety, tolerability and preliminary efficacy of SYS6090 combination therapy in patients with hepatocellular carcinoma. Subject recruitment and screening are underway.\nBased on outcomes from this study, CSPC plans to advance SYS6090 into a Phase III trial to further confirm efficacy and safety in the same indication. The company is currently coordinating additional centres to expand patient enrolment across China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}